Endothelin-1 and the Kidney--beyond BP

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2012 Jun 8

PMID 22670597

Citations 36

Authors

Neeraj Dhaun

David J Webb

David C Kluth

Affiliations

Soon will be listed here.

Abstract

Since its discovery over 20 years ago endothelin-1 (ET-1) has been implicated in a number of physiological and pathophysiological processes. Its role in the development and progression of chronic kidney disease (CKD) is well established and is an area of ongoing intense research. There are now available a number of ET receptor antagonists many of which have been used in trials with CKD patients and shown to reduce BP and proteinuria. However, ET-1 has a number of BP-independent effects. Importantly, and in relation to the kidney, ET-1 has clear roles to play in cell proliferation, podocyte dysfunction, inflammation and fibrosis, and arguably, these actions of ET-1 may be more significant in the progression of CKD than its prohypertensive actions. This review will focus on the potential role of ET-1 in renal disease with an emphasis on its BP-independent actions.

Citing Articles

Weibel-Palade bodies: function and role in thrombotic thrombocytopenic purpura and in diarrhea phase of STEC-hemolytic uremic syndrome.

Monnens L Pediatr Nephrol. 2024; 40(1):5-13.

PMID: 38967838 PMC: 11584422. DOI: 10.1007/s00467-024-06440-3.

Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy.

Reily C, Moldoveanu Z, Pramparo T, Hall S, Huang Z, Rice T Am J Physiol Renal Physiol. 2024; 326(5):F862-F875.

PMID: 38511222 PMC: 11381021. DOI: 10.1152/ajprenal.00253.2023.

Machine learning application identifies plasma markers for proteinuria in metastatic colorectal cancer patients treated with Bevacizumab.

Yu Z, Xu H, Feng M, Chen L Cancer Chemother Pharmacol. 2024; 93(6):587-593.

PMID: 38402561 DOI: 10.1007/s00280-024-04655-7.

Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy.

Nagasawa H, Ueda S, Suzuki H, Jenkinson C, Fukao Y, Nakayama M Nephrol Dial Transplant. 2024; 39(9):1494-1503.

PMID: 38271614 PMC: 11361813. DOI: 10.1093/ndt/gfae021.

Physiologically-based pharmacokinetic model of sparsentan to evaluate drug-drug interaction potential.

Patel N, Chen K, Chen S, Liu K CPT Pharmacometrics Syst Pharmacol. 2023; 13(2):317-329.

PMID: 38041499 PMC: 10864932. DOI: 10.1002/psp4.13086.

References

CHOU S, Porush J . Renal actions of endothelin-1 and endothelin-3: interactions with the prostaglandin system and nitric oxide. Am J Kidney Dis. 1995; 26(1):116-23. DOI: 10.1016/0272-6386(95)90164-7. View

Radford Jr M, Donadio Jr J, Bergstralh E, Grande J . Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol. 1997; 8(2):199-207. DOI: 10.1681/ASN.V82199. View

Boffa J, Tharaux P, Dussaule J, Chatziantoniou C . Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension. 2001; 37(2 Pt 2):490-6. DOI: 10.1161/01.hyp.37.2.490. View

Plato C, Pollock D, Garvin J . Endothelin inhibits thick ascending limb chloride flux via ET(B) receptor-mediated NO release. Am J Physiol Renal Physiol. 2000; 279(2):F326-33. DOI: 10.1152/ajprenal.2000.279.2.F326. View

Benigni A, Perico N, Gaspari F, Zoja C, Bellizzi L, Gabanelli M . Increased renal endothelin production in rats with reduced renal mass. Am J Physiol. 1991; 260(3 Pt 2):F331-9. DOI: 10.1152/ajprenal.1991.260.3.F331. View

Collino F, Bussolati B, Gerbaudo E, Marozio L, Pelissetto S, Benedetto C . Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol Renal Physiol. 2008; 294(5):F1185-94. DOI: 10.1152/ajprenal.00442.2007. View

Odoux C, Crestani B, Lebrun G, Rolland C, Aubin P, Seta N . Endothelin-1 secretion by alveolar macrophages in systemic sclerosis. Am J Respir Crit Care Med. 1997; 156(5):1429-35. DOI: 10.1164/ajrccm.156.5.96-11004. View

Bohle A, Wehrmann M, Bogenschutz O, Batz C, VOGL W, Schmitt H . The long-term prognosis of the primary glomerulonephritides. A morphological and clinical analysis of 1747 cases. Pathol Res Pract. 1992; 188(7):908-24. DOI: 10.1016/s0344-0338(11)80252-9. View

Orth S, Amann K, Gehlen F, Unger L, Wagner J, Raschack M . Adult human mesangial cells (HMCs) express endothelin-B-receptors which mediate endothelin-1-induced cell growth. J Cardiovasc Pharmacol. 2000; 36(5 Suppl 1):S232-7. DOI: 10.1097/00005344-200036051-00069. View

10.

Ehrenreich H, Anderson R, Fox C, Rieckmann P, Hoffman G, Travis W . Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med. 1990; 172(6):1741-8. PMC: 2188743. DOI: 10.1084/jem.172.6.1741. View

11.

Kaw S, Hecker M, Vane J . The two-step conversion of big endothelin 1 to endothelin 1 and degradation of endothelin 1 by subcellular fractions from human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A. 1992; 89(15):6886-90. PMC: 49609. DOI: 10.1073/pnas.89.15.6886. View

12.

Fligny C, Barton M, Tharaux P . Endothelin and podocyte injury in chronic kidney disease. Contrib Nephrol. 2011; 172:120-138. DOI: 10.1159/000328692. View

13.

Watson A, Li J, Schumacher C, de Gasparo M, Feng B, Thomas M . The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia. 2009; 53(1):192-203. DOI: 10.1007/s00125-009-1540-3. View

14.

Sakamoto H, Sasaki S, Hirata Y, Imai T, Ando K, Ida T . Production of endothelin-1 by rat cultured mesangial cells. Biochem Biophys Res Commun. 1990; 169(2):462-8. DOI: 10.1016/0006-291x(90)90354-p. View

15.

Gasic S, Wagner O, Vierhapper H, Nowotny P, Waldhausl W . Regional hemodynamic effects and clearance of endothelin-1 in humans: renal and peripheral tissues may contribute to the overall disposal of the peptide. J Cardiovasc Pharmacol. 1992; 19(2):176-80. DOI: 10.1097/00005344-199202000-00004. View

16.

Mallick N, Short C, Hunt L . How far since Ellis? The Manchester Study of glomerular disease. Nephron. 1987; 46(2):113-24. DOI: 10.1159/000184325. View

17.

Barton M . Reversal of proteinuric renal disease and the emerging role of endothelin. Nat Clin Pract Nephrol. 2008; 4(9):490-501. DOI: 10.1038/ncpneph0891. View

18.

Morigi M, Buelli S, Angioletti S, Zanchi C, Longaretti L, Zoja C . In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol. 2005; 166(5):1309-20. PMC: 1606387. DOI: 10.1016/S0002-9440(10)62350-4. View

19.

Ahn D, Ge Y, Stricklett P, Gill P, Taylor D, Hughes A . Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest. 2004; 114(4):504-11. PMC: 503768. DOI: 10.1172/JCI21064. View

20.

Saleh M, Boesen E, Pollock J, Savin V, Pollock D . Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes. Diabetologia. 2010; 54(4):979-88. PMC: 3804244. DOI: 10.1007/s00125-010-2021-4. View